Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

pilsco ltd - buprenorphine hydrochloride - sublingual tablet - 8mg

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - dermatophagoides farinae allergen extract 50 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 50 ir ((european house dust mite)); dermatophagoides farinae allergen extract 150 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 150 ir ((dermatophagoides pteronyssinus)) - sublingual tablet - 100ir & 300ir - active: dermatophagoides farinae allergen extract 50 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 50 ir ((european house dust mite)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose active: dermatophagoides farinae allergen extract 150 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 150 ir ((dermatophagoides pteronyssinus)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - actair is indicated for the treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - dermatophagoides farinae allergen extract 150 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 150 ir ((european house dust mite)) - sublingual tablet - 300 ir - active: dermatophagoides farinae allergen extract 150 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 150 ir ((european house dust mite)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - actair is indicated for the treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - phleum pratense, quantity: 75000 sq-t - tablet - excipient ingredients: gelatin; mannitol; sodium hydroxide; purified water - grazax is indicated for disease modifying treatment of grass pollen (phleum pratense or allergens cross reacting with p. pratense) induced allergic rhinitis with or without conjunctivitis in adults, adolescents and children above the age of 5 years.

Marekani - Kiingereza - NLM (National Library of Medicine)

contract pharmacy services-pa - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 2 mg - buprenorphine hydrochloride sublingual tablets are indicated for the treatment of opioid dependence and are preferred for induction. buprenorphine hydrochloride sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. under the drug addiction treatment act (data) codified at 21 u.s.c. 823(g), prescription use of this product in the treatment of opioid dependence is limited to healthcare providers who meet certain qualifying requirements, and who have notified the secretary of health and human services (hhs) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. buprenorphine hydrochloride sublingual tablets should not be administered to patients who have been shown to be hypersensitive to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - poa pratensis, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; phleum pratense, quantity: 20 %; dactylis glomerata, quantity: 20 %; lolium perenne, quantity: 20 % - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - lolium perenne, quantity: 20 %; phleum pratense, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; dactylis glomerata, quantity: 20 %; poa pratensis, quantity: 20 % - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - glyceryl trinitrate - sublingual tablet - 500microgram

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - glyceryl trinitrate - sublingual tablet - 300microgram

Marekani - Kiingereza - NLM (National Library of Medicine)

par pharmaceutical, inc. - zolpidem tartrate (unii: wy6w63843k) (zolpidem - unii:7k383oqi23) - zolpidem tartrate 1.75 mg - zolpidem tartrate sublingual tablets are indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. limitations of use: zolpidem tartrate sublingual tablets are not indicated for the treatment of middle-of-the-night insomnia when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking. zolpidem tartrate is contraindicated in patients who have experienced complex sleep behaviors after taking zolpidem tartrate [see warnings and precautions (5.1)]. zolpidem tartrate is contraindicated in patients with known hypersensitivity to zolpidem. observed reactions with zolpidem include anaphylaxis and angioedema [see warnings and precautions (5.4)]. pregnancy category c there are no adequate and well-controlled studies of zolpidem in pregnant women. studies in children to assess the effects of prenatal exposure to zolpidem have not been conducted; however, cases of severe neonatal respiratory depression ha